PREDILIFE SA (ALPRE.PA) Stock Price & Overview
EPA:ALPRE • FR0010169920
Current stock price
The current stock price of ALPRE.PA is 3.14 EUR. Today ALPRE.PA is down by 0%. In the past month the price increased by 0.32%. In the past year, price decreased by -12.53%.
ALPRE.PA Key Statistics
- Market Cap
- 12.34M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.99
- Dividend Yield
- N/A
ALPRE.PA Stock Performance
ALPRE.PA Stock Chart
ALPRE.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ALPRE.PA. When comparing the yearly performance of all stocks, ALPRE.PA is a bad performer in the overall market: 85.46% of all stocks are doing better.
ALPRE.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALPRE.PA. ALPRE.PA may be in some trouble as it scores bad on both profitability and health.
ALPRE.PA Earnings
ALPRE.PA Forecast & Estimates
9 analysts have analysed ALPRE.PA and the average price target is 21.34 EUR. This implies a price increase of 579.57% is expected in the next year compared to the current price of 3.14.
For the next year, analysts expect an EPS growth of -10.83% and a revenue growth 50.7% for ALPRE.PA
ALPRE.PA Groups
Sector & Classification
ALPRE.PA Financial Highlights
Over the last trailing twelve months ALPRE.PA reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS increased by 20.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -290.42% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALPRE.PA Ownership
ALPRE.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 31.06 | 44.565B | ||
| ARGX | ARGENX SE | 29.75 | 44.006B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.431B | ||
| 2X1 | ABIVAX SA | N/A | 8.246B | ||
| ABVX | ABIVAX SA | N/A | 7.961B | ||
| GLPG | GALAPAGOS NV | N/A | 1.638B | ||
| GXE | GALAPAGOS NV | N/A | 1.612B | ||
| NANO | NANOBIOTIX | N/A | 1.342B | ||
| PHGN | PHARMING GROUP NV | 49.55 | 1.054B | ||
| PHARM | PHARMING GROUP NV | 48.33 | 1.05B | ||
| IVA | INVENTIVA SA | N/A | 1.004B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 996.493M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 991.483M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALPRE.PA
Company Profile
Predilife SA operates as a medical technology company. The company is headquartered in Villejuif, Ile-De-France and currently employs 27 full-time employees. The company went IPO on 2018-12-21. The firm operates mainly in the field of oncology. Predilife offers MammoRisk, which is a predictive breast cancer test that combines medical imaging thanks to a proprietary software, DenSeeMammo, Big Data and statistics through a scoring tool and genetic profiles via a polygenic risk score (PRS). The image is analysed in order to extract the breast density and the first breast cancer risk factor. In addition, The technology used by MammoRisk makes it possible to evaluate from a database of individuals tracked over time, the risks of an individual to develop cancer compared to the fate of his/her closest neighbors through a database of a number of American and French women.
Company Info
IPO: 2018-12-21
PREDILIFE SA
Igr Campus Cancer 1 Batiment Maurice, 39 Rue Camille Desmoulins
Villejuif ILE-DE-FRANCE FR
Employees: 27
Phone: 33142114211.0
PREDILIFE SA / ALPRE.PA FAQ
Can you describe the business of PREDILIFE SA?
Predilife SA operates as a medical technology company. The company is headquartered in Villejuif, Ile-De-France and currently employs 27 full-time employees. The company went IPO on 2018-12-21. The firm operates mainly in the field of oncology. Predilife offers MammoRisk, which is a predictive breast cancer test that combines medical imaging thanks to a proprietary software, DenSeeMammo, Big Data and statistics through a scoring tool and genetic profiles via a polygenic risk score (PRS). The image is analysed in order to extract the breast density and the first breast cancer risk factor. In addition, The technology used by MammoRisk makes it possible to evaluate from a database of individuals tracked over time, the risks of an individual to develop cancer compared to the fate of his/her closest neighbors through a database of a number of American and French women.
What is the current price of ALPRE stock?
The current stock price of ALPRE.PA is 3.14 EUR.
What is the dividend status of PREDILIFE SA?
ALPRE.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALPRE stock?
ALPRE.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy ALPRE stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALPRE.PA.
Can you provide the growth outlook for PREDILIFE SA?
The Revenue of PREDILIFE SA (ALPRE.PA) is expected to grow by 50.7% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for PREDILIFE SA?
PREDILIFE SA (ALPRE.PA) has a market capitalization of 12.34M EUR. This makes ALPRE.PA a Nano Cap stock.